Recent Updates
Recently added Catalysts

Otelixizumab

Phase 3

Diabetes Mellitus, Type 1 | Monoclonal antibody | Metabolic |GSK plc|Last Updated: Jun 24, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment242
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01123083Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2PHASE3 COMPLETED 179May 17, 2010Mar 9, 2012Sep 15, 20171 Italy
NCT02000817Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus PatientsPHASE1 COMPLETED 30Mar 12, 2014Sep 27, 2018Jun 24, 20196 Belgium
NCT00946257Subcutaneous Administration of Otelixizumab to T1DM PatientsPHASE1 COMPLETED 33Jul 8, 2009Jun 25, 2013Jun 1, 20176 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide Area Under Curve (AUC) (Normalized for 120-minute Time Interval) at Month 12
Baseline (Day 1) and Month 12

C-peptide is a protein that shows how much insulin the body is producing. For 3 days before the mixed meal tolerance test participants were asked to eat a balanced diet. The test was performed only when the finger-stick blood glucose level was above 70 mg per deciliter (mg/dL) and no higher than 200 mg/dL. Mixed meal-stimulated C-peptide AUC was the area under the C-peptide/time curve from time 0 to 120-minutes, calculated using the trapezoidal rule. This AUC was normalized for time interval by dividing it by 120-minutes (the number of minutes over which it was determined), and was adjusted by inclusion of Baseline C-peptide AUC as a covariate in the analysis. Baseline was defined at Day 1. Change from Baseline was calculated by subtracting the value at Month 12 from the Baseline value.

Number of Participants With Adverse Events (AEs) Related to Cytokine Release Syndrome (CRS)
Up to Day 14

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. On treatment AEs have been reported. Safety Population comprised of all participants who received at least one dose of study treatment.

Epstein-Barr Virus (EBV) Viral Load Detection
Week 3, Week 6, Week 8, Week 12, Week 24 and Week 96

Blood samples were collected for analysis of EBV viral load and detection was done by polymerase chain reaction (PCR).

Number of Participants With Abnormal Laboratory Results
Up to Month 24

Blood samples were collected to analyze the laboratory parameters which included alanine aminotransferase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bilirubin, calcium, chloride, creatinine, direct bilirubin, glucose, potassium, protein, sodium, urate, urea nitrogen, basophil, eosinophil, mean corpuscular haemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), erythrocytes, haematocrit, haemoglobin, leukocytes, lymphocytes, monocytes, neutrophils, platelets and reticulocytes.

Number of Participants With Increase in QT Interval Corrected for Heart Rate (QTc)
Up to Month 24

12-lead electrocardiograms (ECGs) were obtained in semi-supine position after 5 minutes rest for the participants at indicated time points to measure QTc.

Number of Participants With Abnormal Vital Sign Results
Up to Month 24

Vital signs were measured in semi-supine position after 5 minutes rest for the participants at indicated time points. Vital signs included systolic, diastolic blood pressure, pulse rate and respiratory rate

Safety and tolerability after a single dose of otelixizumab in T1DM patients
21 days
Secondary Endpoints
Change From Baseline in 2 Hour Mixed Meal-stimulated C-peptide AUC (Normalized for 120-minute Time Interval) at Week 12 and 6 Months
Baseline (Day 1) and Week 12, Month 6
Change From Baseline in Stimulated C-Peptide Mean AUC at Week 12, Month 6, 12 and 18
Baseline (Day 1) and Week 12, Month 6, 12, 18
Number of Participants With Responder Status
Month 3, 6 and 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
otelixizumabEXPERIMENTALotelixizumab
placeboPLACEBO_COMPARATORplacebo
Otelixizumab 9 mgEXPERIMENTALEach subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
Otelixizumab 18 mgEXPERIMENTALEach subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
Otelixizumab 27 mgEXPERIMENTALEach subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
Otelixizumab 36 mgEXPERIMENTALEach subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
Cohort 1EXPERIMENTAL0.3 mg dose
Cohort 2EXPERIMENTAL0.6 mg dose
Cohort 3EXPERIMENTAL1.2 mg dose
Cohort 4EXPERIMENTAL1.8 mg dose
Cohort 5EXPERIMENTAL2.4 mg dose
Cohort 6EXPERIMENTAL3.0 mg dose
Interventions
NameTypeDescription
OtelixizumabBIOLOGICALinfusion
PlaceboBIOLOGICALInfusion
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — 17 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Ages 12-17 * Diagnosis of diabetes mellitus, consistent with ADA criteria * No more than 90 days between diagnosis and administration of study compounds * Requires insulin for type 1 diabetes mellitus, or has required insulin at some time between diagnosis and administration o...

Countries:ItalyBelgium
Unlock Eligibility Criteria